FDA will review to Genentechs application for Rituxan use in pediatric (age >2yrs) granulomatosis with polyangiitis & microscopic polyangiitis. If approved, this would be the 1st pediatric indication for RTX; data based on ths phase IIa PePRS study https://t.co/rRFiyQNKca